z-logo
open-access-imgOpen Access
Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy
Author(s) -
Eric P. Cohen,
Brian L. Fish,
John E. Moulder
Publication year - 2010
Publication title -
current drug targets
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.826
H-Index - 102
eISSN - 1873-5592
pISSN - 1389-4501
DOI - 10.2174/1389450111009011423
Subject(s) - medicine , nephropathy , captopril , renin–angiotensin system , losartan , bradykinin , angiotensin converting enzyme , angiotensin ii , cancer research , pharmacology , endocrinology , receptor , diabetes mellitus , blood pressure
Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here